Recent Updates — AARD
The FDA lifted the full clinical hold on Aardvark Therapeutics' investigational drug ARD-101, allowing the company to resume clinical development for hyperphagia in patients with Prader-Willi syndrome. The regulatory clearance follows a review of exploratory efficacy and safety data from the terminated Phase 3 HERO trial and its open-label extension. Aardvark plans to request an FDA meeting to align on the design of a new Phase 3 program, with clinical activities expected to resume in 2027. The company operates as a clinical-stage biopharmaceutical firm developing small-molecule therapeutics for hunger suppression.
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics’ Investigational New Drug application for ARD-101, allowing the resumption of clinical development for hyperphagia in Prader-Willi Syndrome. The hold was placed in May 2026 following reversible ECG changes observed in healthy volunteers; subsequent safety studies showed no cardiac events at doses up to 400 mg twice daily. Aardvark plans to engage with the FDA on Phase 3 trial design and will host a webcast on October 23, 2026, to review data from the terminated HERO and OLE trials. Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for hunger-associated disorders.
The board appointed David Zhang, Ph.D., MBA, as a Class II director effective October 7, 2026. Dr. Zhang brings over 25 years of experience in clinical strategy and biostatistics from roles at Abivax S.A., Alumis Inc., MyoKardia, and Genentech/Roche. He receives $40,000 annually plus a stock option valued at $500,000 that vests monthly over three years with full acceleration upon a change in control. Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases and Prader-Willi Syndrome.
Aardvark Therapeutics held its Annual Meeting on August 14, 2026, with 54.79% of outstanding shares voting. Stockholders elected Victor Tong, Jr. and Jeffrey Chi as Class I directors and ratified BDO USA, P.C. as the independent auditor. Crucially, shareholders approved the repricing of certain outstanding stock options under the Company's equity incentive plans. This corporate action modifies existing compensation agreements for eligible participants. Aardvark Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
Aardvark Therapeutics reported second quarter 2026 financial results, including a net loss of $14.4 million and cash reserves of $73.9 million sufficient to fund operations into late 2027. The company terminated its Phase 3 HERO and Open Label Extension trials for ARD-101 in June 2026 following a full clinical hold placed by the FDA in May 2026. Aardvark plans to assess unblinded data from these trials in the third quarter of 2026 to determine next steps while maintaining active discussions with regulators regarding the clinical hold.
Aardvark Therapeutics, Inc. entered into retention bonus agreements with CFO/COO Nelson Sun and CMO Dr. Manasi Jaiman on June 10, 2026. Mr. Sun is entitled to a $346,500 cash bonus, including a $198,000 annual bonus and $153,000 retention bonus, payable on January 1, 2027. Dr. Jaiman is entitled to a $357,000 cash bonus, including a $204,000 annual bonus and $153,000 retention bonus, payable on January 1, 027. Aardvark Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.